LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION [Accessibility Statement] Skip NavigationShareholders Who Purchased INO Securities During Class Period Urged to Review OptionsNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO).YOU MAY BE AFFECTED IF YOU:- Acquired shares during the Class Period- Lost money on your Inovio inves ...

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The su ...

Core Insights - The pharmaceutical giant is entering a partnership with Vivtex to license drug-delivery technologies aimed at developing next-generation oral medications for obesity, diabetes, and related diseases [1] Group 1 - The collaboration focuses on enhancing drug-delivery systems to improve the efficacy of oral medications [1] - The targeted diseases include obesity and diabetes, which are significant health concerns globally [1] - This partnership may position the company to capture a larger market share in the growing sector of oral medications for chronic diseases [1]

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. The invitation-only event will c ...

Achieved record annual revenue of $4.3 billion in 2025, driven by the successful launch of Modeyso and double-digit growth in the Xywav and Zepzelca franchises. Management is sharpening the corporate focus on rare disease, leveraging existing capabilities in sleep, epilepsy, and oncology to drive long-term value through internal R&D and M&A. Resolved significant legal headwinds by settling ANDA litigation for Epidiolex, extending the product's runway into the late 2030s, and settling the majority of r ...

Ironwood Pharmaceuticals Q4 and FY 2025 Investor Update February 25, 2026 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our mission; our strategy, business, financial position and operations; our ability to drive growth and profitability; the commercial potentia ...

Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record 2025 revenues of $719 million, successfully transitioning the business model following the loss of exclusivity for legacy products Trokendi XR and Oxtellar XR. Growth was primarily driven by a 40% revenue increase across four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now represent 76% of total revenues. Successfully integrated the Sage Therapeutics acqui ...

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[Vivtex Corporation]FollowFeb 25 (Reuters) - Danish drugma ...

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the completion of a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. Th ...

Fourth Quarter and Year-End 2025 Financial Results & Business Update February 25, 2026 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, ...